Evidence map›Paper›PMID 42467062›Full record

ReviewInfection and immunity2026

Balancing act of cytokines in controlling the severity of

Kevin S Mears, Michael C Abt

Abstract readReview
In one paragraph

Review in Infection and immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kevin S MearsDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Michael C AbtDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-7351-2061

Funding

Project 3: Defining adaptive immune interactions that shape Clostridioides difficile infectionU19AI174998 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI DREW WEISSMAN · 2023 to 2026
$7.6M
Investigating Immune-Microbiome interactions during treatment of Clostridioides difficile with fecal microbiome transplantationR01AI158830 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ABT, MICHAEL C. · 2021 to 2025
$2.4M
Investigating the role of interferon lambda in protection against severe Clostridioides difficile infectionF31DK138546 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI MEARS, KEVIN STANTON · 2024 to 2025
$73k
National Institute of Allergy and Infectious Diseases R01 AI158830, U19 AI174998NIAID NIH HHS R01 AI158830NIAID NIH HHS U19 AI174998NIDDK NIH HHS F31 DK138546NIDDK NIH HHS F31-DK138546
6 · The paper itself

Abstract

The severity of

Indexed as

Clostridioides difficileClostridium InfectionsCytokinesAnimalsHost-Pathogen InteractionsHumansImmunity, InnateCytokinesClostridium difficilecytokines

Identifiers

PMID42467062
PMCPMC13459931

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.